Aptevo Therapeutics Inc. 8-K

What Happened
Aptevo Therapeutics Inc. announced on June 29, 2026 that it entered a Grant Award Agreement with the Andy Hill Cancer Research Endowment (CARE) Fund. The Grantor will provide $1,499,951 on a reimbursement basis to support IND‑enabling studies for APVO451, Aptevo’s trispecific antibody candidate for solid tumors. The project period is expected to run through June 2028, subject to earlier termination under the agreement. Aptevo disclosed the grant in an 8-K and issued a press release on June 30, 2026.

Key Details

• Grant amount: $1,499,951 provided by the Andy Hill CARE Fund.
• Funding structure: reimbursement-only payments tied to eligible costs, an approved budget, specified milestones, and reporting/compliance requirements.
• Matching requirement: funding is contingent on Aptevo providing any applicable non-state matching contributions at least equal to the CARE Fund’s contribution.
• IP and obligations: Aptevo retains ownership of intellectual property generated under the project, subject to acknowledgments and commercialization/public benefit commitments.

Why It Matters
This grant supplies non-dilutive, milestone‑driven funding targeted to advance APVO451 toward an IND application, reducing near-term cash outlays if Aptevo meets project milestones and provides required matching funds. Investors should note the funds are reimbursable (Aptevo must incur costs first), are contingent on milestones and reporting, and are limited in size and duration—so while helpful for development progress, the grant is not a substitute for broader financing needs.